Dj Fulcrum Therapeutics Files 8K - Director, Officer Or Compensation Filing >Fulc

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Grupo Financiero Galicia S.A. GGAL: This financial service holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.4% over the last 60 days.

Grupo Financiero Galicia S.A. Price and Consensus

Grupo Financiero Galicia S.A. price-consensus-chart | Grupo Financiero Galicia S.A. Quote

Gold Fields Limited GFI: This gold mining company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.8% over the last 60 days.

Gold Fields Limited Price and Consensus

Gold Fields Limited price-consensus-chart | Gold Fields Limited Quote

Fulcrum Therapeutics, Inc. FULC: This clinical-stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 39.1% over the last 60 days.

Fulcrum Therapeutics, Inc. Price and Consensus

Fulcrum Therapeutics, Inc. price-consensus-chart | Fulcrum Therapeutics, Inc. Quote

Deckers Outdoor Corporation DECK: This footwear and apparel company has seen the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.

Deckers Outdoor Corporation Price and Consensus

Deckers Outdoor Corporation price-consensus-chart | Deckers Outdoor Corporation Quote

New Gold Inc. NGD: This gold mining company has seen the Zacks Consensus Estimate for its current year earnings increasing 30.8% over the last 60 days.

New Gold Inc. Price and Consensus

New Gold Inc. price-consensus-chart | New Gold Inc. Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Investment Research

Fulcrum Therapeutics FULC, a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter’s loss is pinned at 40 cents per share. The company currently does not have any marketed products and does not record any revenues.

The Zacks Consensus Estimate for Fulcrum’s loss per share has narrowed from 46 cents to 28 cents for 2024 over the past 60 days, while that for 2025 has narrowed from $1.51 to $1.14.

FULC Estimate Movement

FULC’s Earnings Surprise History

Fulcrum’s performance has been impeccable over the trailing four quarters. The company beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 393.18%. In the last reported quarter, the company came up with an earnings surprise of 1,550%.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Fulcrum this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Fulcrum has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stay up-to-date with all quarterly releases:See Zacks Earnings Calendar.

Factors Shaping FULC’s Upcoming Results

In the absence of an approved product, investors can expect updates regarding Fulcrum’s pipeline development on the third-quarter conference call.

During the third quarter, the company faced a major setback when it announced disappointing top-line data from a late-stage study, which evaluated its pipeline candidate, losmapimod, for facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Per the data readout, the phase III REACH study of losmapimod for FSHD did not meet its primary endpoint. The study also failed to achieve nominal statistical significance on the secondary endpoints. Following the disappointing REACH study results, Fulcrum decided to stop the further development of losmapimod in FSHD.

Having scraped the FSHD program, Fulcrum has shifted its focus to pociredir, which is currently being developed in an early-stage study for treating patients with sickle cell disease (SCD), an inherited blood disorder.

Pocirediris is an investigational oral small-molecule inhibitor of embryonic ectoderm development and Fulcrum’s only clinical-stage pipeline candidate. It was developed using the company’s proprietary drug discovery technology, FulcrumSeek. FULC is currently evaluating four once-daily dosage strengths of pociredir (2 mg, 6 mg, 12 mg and 20 mg) in separate cohorts in a phase Ib study to treat SCD. Each cohort is expected to enroll approximately 10 patients. Top-line data from this study is expected in 2025.

SCD offers a lucrative market space for Fulcrum despite the presence of approved products. Vertex VRTX and CRISPR Therapeutics CRSP market their one-time gene therapy for SCD and transfusion-dependent beta thalassemia, Casgevy(exa-cel). Notably, Casgevy was approved in multiple geographies in 2023 and early 2024, including the United States and the EU. bluebird bio BLUE also markets its own SCD therapy under the brand name, Lyfgenia (lovo-cel). BLUE’s Lyfgenia has a different mechanism of action than that of VRTX/CRSP’s Casgevy. Several other biotech firms are also currently developing SCD treatments.

FULC’s Price Performance & Attractive Valuation

The stock has plummeted 52% in the year-to-date period compared with the industry’s 3.5% decline. FULC has also underperformed in the sector and the S&P 500 in the same period, as seen in the chart below.

FULC Stock Underperforms the Industry, Sector & the S&P 500